Literature DB >> 27057732

LXR activation protects hippocampal microvasculature in very old triple transgenic mouse model of Alzheimer's disease.

Adrián G Sandoval-Hernández1, Alejandro Restrepo1, Gloria P Cardona-Gómez2, Gonzalo Arboleda3.   

Abstract

The vascular hypothesis of Alzheimer's disease postulates that disruption of the brain microvasculature is important for the accumulation of amyloid beta and increased neuroinflammation. Liver X Receptor agonist, GW3965, has been demonstrated to successfully modulate neuroinflammation and lipid metabolism in murine models of AD. This is partially due to increased expression of ApoE levels and increased mobility of endothelial progenitor cells. This paper analyzes changes in the neurovascular unit and in astrocytes and microglia markers following oral administration of GW3965 in a very old triple transgenic AD mice (3xTg-AD mice). We found that astrogliosis, but not activation of microglia, decreased in very old (24 months) 3xTg-AD mice treated with GW965. In addition, GW3965 increased LRP1 levels in neuron-like cells and partially restored microvascular morphology by decreasing tortuosity and increasing length as shown by Lectin immunostaining. Interestingly, these changes were associated with decreased Aβ in blood vessels. In conclusion, short-term treatment of 3xTg-AD mice with GW3965 restored microvascular architecture which may be important in the cognitive improvement previously shown.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; GW3965; Liver x receptors; Neuroinflammation; Neurovascular endothelium

Mesh:

Substances:

Year:  2016        PMID: 27057732     DOI: 10.1016/j.neulet.2016.04.007

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.

Authors:  Radha Desai; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2019-08-09       Impact factor: 8.739

Review 2.  Transcriptional control of microglia phenotypes in health and disease.

Authors:  Inge R Holtman; Dylan Skola; Christopher K Glass
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

Review 3.  Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease.

Authors:  Nicholas F Fitz; Kyong Nyon Nam; Radosveta Koldamova; Iliya Lefterov
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

4.  Human geroprotector discovery by targeting the converging subnetworks of aging and age-related diseases.

Authors:  Jialiang Yang; Shouneng Peng; Bin Zhang; Sander Houten; Eric Schadt; Jun Zhu; Yousin Suh; Zhidong Tu
Journal:  Geroscience       Date:  2019-10-21       Impact factor: 7.713

Review 5.  Remembering your A, B, C's: Alzheimer's disease and ABCA1.

Authors:  Cutler T Lewandowski; Megan S Laham; Gregory R J Thatcher
Journal:  Acta Pharm Sin B       Date:  2022-01-24       Impact factor: 14.903

6.  Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

Authors:  Miguel Moutinho; Juan F Codocedo; Shweta S Puntambekar; Gary E Landreth
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-12       Impact factor: 13.820

7.  The pleiotropic vasoprotective functions of high density lipoproteins (HDL).

Authors:  Guilaine Boyce; Emily Button; Sonja Soo; Cheryl Wellington
Journal:  J Biomed Res       Date:  2017-05-26

8.  Liver X Receptor Alpha Is Important in Maintaining Blood-Brain Barrier Function.

Authors:  Elien Wouters; Nienke M de Wit; Jasmine Vanmol; Susanne M A van der Pol; Bert van Het Hof; Daniela Sommer; Melanie Loix; Dirk Geerts; Jan Ake Gustafsson; Knut R Steffensen; Tim Vanmierlo; Jeroen F J Bogie; Jerome J A Hendriks; Helga E de Vries
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.